MannKind Corporation (NASDAQ:MNKD) Files An 8-K Other Events
Item 8.01 Other Events.

On January 6, 2017, MannKind Corporation (the “Company”) received $30.6 million to the terms of the Settlement Agreement entered with sanofi-aventis U.S. LLC (“Sanofi”) on November 9, 2016 as acceleration and in replacement of all other payments that Sanofi would otherwise have been required to make in the future to the insulin put option, without the Company being required to deliver any insulin for such payment.

About MannKind Corporation (NASDAQ:MNKD)

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company’s fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

MannKind Corporation (NASDAQ:MNKD) Recent Trading Information

MannKind Corporation (NASDAQ:MNKD) closed its last trading session up +0.012 at 0.643 with 3,107,595 shares trading hands.